PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT- A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.2533
https://www.valueinhealthjournal.com/article/S1098-3015(18)35835-2/fulltext
Title :
PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT- A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35835-2&doi=10.1016/j.jval.2018.09.2533
First page :
Section Title :
Open access? :
No
Section Order :
1887